Abstract
Alzheimers disease (AD) is a complex neurodegenerative disorder pathologically identified by the presence of extracellular senile plaques (SP) with a proteinaceous core composed of aggregates of the amyloid peptide (Aβ) and intracellular aggregates of the microtubule-associated protein tau (τ) as neurofibrillary tangles (NFTs). These hallmarks consist of abnormally folded proteinaceous components that are believed to be neurotoxic in AD. The mechanisms of toxicity remain unclear although oxidative stress and inflammation are implicated as mediators of the toxicity and these lesions, in turn, are known to damage cellular components including proteins, lipids in the membrane and DNA. However effects on genotoxicity and its role in AD are less clear. The present review discusses various influences, in particular of amyloid, on the genetic material and their possible role in the neurodegeneration in AD. Further, the amalgamation of genomics and proteomics in understanding AD and therapeutic development is suggested.
Keywords: Alzheimer's disease, mutations, amyloid beta, DNA damage, 8OHdG, gene expression, cell cycle, p53
Current Alzheimer Research
Title: Genotoxicity in Alzheimers Disease: Role of Amyloid
Volume: 3 Issue: 4
Author(s): Anitha Suram, Chitra Venugopal, Annamalai Prakasam and Kumar Sambamurti
Affiliation:
Keywords: Alzheimer's disease, mutations, amyloid beta, DNA damage, 8OHdG, gene expression, cell cycle, p53
Abstract: Alzheimers disease (AD) is a complex neurodegenerative disorder pathologically identified by the presence of extracellular senile plaques (SP) with a proteinaceous core composed of aggregates of the amyloid peptide (Aβ) and intracellular aggregates of the microtubule-associated protein tau (τ) as neurofibrillary tangles (NFTs). These hallmarks consist of abnormally folded proteinaceous components that are believed to be neurotoxic in AD. The mechanisms of toxicity remain unclear although oxidative stress and inflammation are implicated as mediators of the toxicity and these lesions, in turn, are known to damage cellular components including proteins, lipids in the membrane and DNA. However effects on genotoxicity and its role in AD are less clear. The present review discusses various influences, in particular of amyloid, on the genetic material and their possible role in the neurodegeneration in AD. Further, the amalgamation of genomics and proteomics in understanding AD and therapeutic development is suggested.
Export Options
About this article
Cite this article as:
Suram Anitha, Venugopal Chitra, Prakasam Annamalai and Sambamurti Kumar, Genotoxicity in Alzheimers Disease: Role of Amyloid, Current Alzheimer Research 2006; 3 (4) . https://dx.doi.org/10.2174/156720506778249380
DOI https://dx.doi.org/10.2174/156720506778249380 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke
Current Pharmaceutical Design Postischemic-Anoxic Encephalopathy After Global Forebrain Ischemia
Central Nervous System Agents in Medicinal Chemistry Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Oxidative Stress Targeting Amyloid Beta Accumulation and Clearance in Alzheimer’s Disease: Insight into Pathological Mechanisms and Therapeutic Strategies
Current Psychopharmacology Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Catechol-O-methyltransferase, Cognition and Alzheimer's Disease
Current Alzheimer Research Calpain and Its Involvement in the Pathophysiology of CNS Injuries and Diseases: Therapeutic Potential of Calpain Inhibitors for Prevention of Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Recent Patents in Diagnosis and Treatment for Inborn Errors of Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Treatment Strategies Against Diabetic Foot Ulcer: Success so Far and the Road Ahead
Current Diabetes Reviews Multiple Sclerosis Therapy Monitoring Based on Gene Expression
Current Pharmaceutical Design Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science